Conflict of interest
Pierre, HIV, hepatitis
STIS, BROWN
Matthew G. Johnson, Julie M. Strizki, Michelle L. Brown, Hong Wan (at the time of study), Hala H. Shamsuddin, Angela Williams-Diaz, Jiejun Du (at the time of study), Jay A. Grobler, Amanda Paschke, and Carisa De Anda are employees of Merck & Co., Inc., Rahway, NJ, USA. Moti Ramgopal: Consulting fees: Gilead, Merck, ViiV, Janssen; Honoraria: Gilead, ViiV, Janssen. Diana F. Florescu: Grants: Merck, Regeneron, Astellas, Novavax, Bavarian Nordic, Takeda, SymBio, NobelPharma, AlloVir. Consulting fees: Takeda and Merck; Data Safety Monitoring Board/Advisory Board: Medpace. Pierre Delobel: Travel grants: BMS, Gilead, MSD, and Janssen in the last 5 years; Society: HAS/ANRS-MIE/CNS: French recommendations for treatment and prevention of HIV, hepatitis, and STIs; Scientific Committee: ANRS-MIE (CSS13). Ilsiyar Khaertynova: Nothing to disclose. José F. Flores: Nothing to disclose. Leon F. Fouche: Nothing to disclose. Shan-Chwen Chang: Nothing to disclose.